Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Destiny Pharma’s Vision is of an expanding range of new antimicrobial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due to the existence or threat of antibiotic resistance.
Destiny Pharma is an AIM listed (AIM:DEST) company based in Brighton, United Kingdom.
The Downing FOUR VCT PLC Healthcare Technology Fund is managed by Downing LLP